树突状细胞联合细胞因子诱导的杀伤细胞治疗晚期非小细胞肺癌的近期疗效观察  

Efficacy of DC-CIK for the treatment of advanced non-small cell lung cancer

作　　者：陈东升[1] 吴光兴[1] 

机构地区：[1]广东省湛江中心人民医院肿瘤防治中心,湛江524037

出　　处：《中国肿瘤临床与康复》2015年第3期264-266,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨树突状细胞(DC)联合细胞因子诱导的杀伤细胞(CIK)治疗晚期非小细胞肺癌(NSCLC)的近期疗效。方法选取2011年1月至2014年1月间确诊并接受治疗的80例晚期非小细胞肺癌患者,随机分为对照组和试验组。对照组患者接受单纯化疗;而试验组患者在常规化疗的基础上,采用树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)治疗。比较两组患者治疗前后的肿瘤改善率和不良反应发生率,并比较两组患者出院后的生活质量。结果治疗周期结束后,试验组患者的肿瘤改善状况明显优于对照组,且不良反应发生率较低。患者出院1年后,试验组患者的生活质量明显高于对照组,差异有统计学意义(P<0.05)。结论晚期NSCLC在化疗的基础上采用DC-CIK治疗,可以有效改善肿瘤状况,提高患者免疫力,有效减少不良反应,提高患者的生活质量,值得临床进一步推广。Objective To investigate the efficacy of DC-CIK for the treatment of advanced nonsmall cell lung cancer and provide reference for the treatment of lung cancer. Methods 80 patients with advanced non-small cell lung cancer were collected and randomly divided into control group and observation group from January 2011 to January 2014. The control group patients received routine treatment,while the observation group received DC-CIK treatment on the basis of routine treatment. The improvement of cancer,incidence of adverse effects and quality of life of both groups were compared after treatment. Results The improvement of observation group with lower incidence of adverse complications was better than that of control group after treatment. The quality of life of observation group was better than that of control group after1 year leaving hospital（ P〈0. 05）. Conclusion DC-CIK therapy can effectively ameliorate tumor,improve immunity,effectively reduce the occurrence of adverse complications and improve patient＇s quality of life. It is worthy of clinical promotion and application.

关 键 词：树突状细胞 细胞因子诱导的杀伤细胞 癌 非小细胞肺 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]